Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$474K Buy
1,310
+122
+10% +$41.8K 0.03% 362
2026
Q1
$418K Sell
1,188
-410
-26% -$146K 0.03% 339
2025
Q4
$523K Buy
1,598
+680
+74% +$216K 0.04% 290
2025
Q3
$259K Sell
918
-76
-8% -$22K 0.02% 384
2025
Q2
$277K Sell
994
-96
-9% -$27.2K 0.02% 373
2025
Q1
$340K Buy
+1,090
New +$322K 0.03% 301
2024
Q4
– Sell
-685
Closed -$221K – 364
2024
Q3
$221K Sell
685
-53
-7% -$17.3K 0.02% 331
2024
Q2
$231K Buy
+738
New +$217K 0.03% 316

Other funds holding AMGN

Waterloo Capital's AMGN Position: Q2 2026 in Review

Waterloo Capital increased its Amgen (AMGN) stake by 10% in Q2 2026, buying an estimated $41.8K and bringing the position to 1,310 shares worth $474K. The position accounts for 0.03% of the portfolio, ranked #362.

Waterloo Capital first reported a position in AMGN in Q2 2024 and has held it in 8 quarters since. The position peaked at $523K in Q4 2025. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Waterloo Capital held 1,310 shares of Amgen worth $474K as of Q2 2026.
  • Waterloo Capital bought 122 Amgen shares in Q2 2026, an estimated $41.8K.
  • Amgen made up 0.03% of Waterloo Capital's portfolio in Q2 2026, its #362 holding.
  • Waterloo Capital first reported a position in Amgen in Q2 2024 and has held it in 8 quarters since.
  • Waterloo Capital's Amgen position peaked at $523K in Q4 2025.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Waterloo Capital's 13F filing for Q2 2026, filed 29 Jul 2026.